Search
The Kids Research Institute Australia researchers have confirmed that skin infections in many Aboriginal children across northern Western Australia are going unrecognised.
The Wesfarmers Centre has established the Deborah Lehmann Research Award to acknowledge the significant contribution that Clinical Associate Professor Deborah Lehmann AO has made to paediatric infectious disease research.
Dr Janessa Pickering is a research microbiologist with expertise in the molecular diagnostics and host pathogen interactions of upper respiratory tract pathogens that cause disease in children.
Program Manager
An alarming number of Strep A infections are going unnoticed throughout classrooms in Broome and Derby according to a major study by The Kids Research Institute Australia aiming to reduce the burden of acute rheumatic fever (ARF) and rheumatic heart disease (RHD).
Valuable support from the Raine Medical Research Foundation’s 2025 grant round will power four new research projects at The Kids Research Institute Australia.
Acute rheumatic fever (ARF) is a multiorgan inflammatory disorder that results from the body's autoimmune response to pharyngitis or a skin infection caused by Streptococcus pyogenes (Strep A). Acute rheumatic fever mainly affects those in low- and middle-income nations, as well as in indigenous populations in wealthy nations, where initial Strep A infections may go undetected.
Vaccine development and implementation decisions need to be guided by accurate and robust burden of disease data. We developed an innovative systematic framework outlining the properties of such data that are needed to advance vaccine development and evaluation, and prioritize research and surveillance activities.
Group A Streptococcus (Strep A) is responsible for a significant global health and economic burden. The recent prioritization of Strep A vaccine development by the World Health Organization has prompted global research activities and collaborations. To progress this prioritization, establishment of robust surveillance for Strep A to generate updated regional disease burden estimates and to establish platforms for future impact evaluation is essential.
Pulmonary exacerbations are associated with increased morbidity and mortality in people with cystic fibrosis (CF). There is no consensus about which outcomes should be evaluated in studies of pulmonary exacerbations or how these outcomes should be measured.